Caminschi Irina, Lahoud Mireille H, Shortman Ken
The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
Eur J Immunol. 2009 Apr;39(4):931-8. doi: 10.1002/eji.200839035.
mAb that recognise various cell surface receptors have been used to deliver antigen to DC and thereby elicit immune responses. The encouraging data obtained in mouse models suggests that this immunisation strategy is efficient and could lead to clinical trials. We discuss a number of issues pertinent to this vaccination approach. These include which molecules are the best targets for delivering antigen to DC, which DC subtypes should be targeted, the types of immune responses to be generated and whether additional adjuvants are required. Finally, we discuss some progress towards targeting antigen to human DC.
识别各种细胞表面受体的单克隆抗体已被用于将抗原递送至树突状细胞（DC），从而引发免疫反应。在小鼠模型中获得的令人鼓舞的数据表明，这种免疫策略是有效的，并且可能会导致临床试验。我们讨论了与这种疫苗接种方法相关的一些问题。这些问题包括哪些分子是将抗原递送至DC的最佳靶点、应靶向哪些DC亚型、要产生的免疫反应类型以及是否需要额外的佐剂。最后，我们讨论了在将抗原靶向人类DC方面取得的一些进展。
